14 stocks with full analysis pages and real-time alerts
Healthcare is one of the most diverse sectors, spanning large-cap pharmaceutical companies (Pfizer, Johnson & Johnson), biotech innovators (Amgen, Moderna), medical device makers (Intuitive Surgical, Medtronic), and healthcare services providers (UnitedHealth, HCA). The sector benefits from structural tailwinds: aging global populations, expanding insurance coverage, and continuous medical innovation. Biotech stocks can deliver outsized returns when clinical trials succeed but also devastating losses when they fail, making this sector binary for smaller names. Large-cap pharma offers more stability with dividend yields and diversified drug portfolios. The healthcare sector is generally considered defensive since people need medical care regardless of economic conditions, but individual stock movements can be extreme around FDA decisions, patent expirations, and drug pricing legislation.
Biotech investors track pipeline value (number and stage of drug candidates), probability-adjusted net present value of drug portfolios, and cash runway (months of funding remaining). Pharma companies are evaluated on revenue growth, patent cliff exposure (upcoming generic competition), R&D spending as a percentage of revenue, and dividend sustainability. Medical device companies focus on procedure volumes, average selling prices, and hospital capital spending cycles. For all healthcare stocks, P/E ratios relative to growth (PEG ratio) help compare across sub-industries.
Healthcare stocks experience sudden, large moves that are difficult to predict. FDA approval decisions are binary events that can move biotech stocks 30-80% overnight. Clinical trial data releases create similar volatility. Volume alerts are critical for detecting unusual institutional buying or selling before major news. Price alerts at key support and resistance levels help investors manage risk around these catalysts. Without real-time monitoring, healthcare investors often learn about major developments hours after the move has already happened.
For biotech stocks, set price above and price below alerts at key technical levels to catch post-catalyst breakouts or breakdowns. Volume change alerts at 200%+ detect unusual institutional activity that often precedes news. For large-cap pharma, dividend ex-date alerts help income investors capture distributions, while earnings alerts track quarterly performance. New 52-week high alerts identify stocks with sustained momentum from successful drug launches or pipeline progress.
Based on active alerts set by the StockAlert.pro community.
Sorted by market capitalization. Only stocks with full analysis pages are shown.
| Symbol | Company | Price | Change | 52W High | 52W Low | Market Cap | Alert |
|---|---|---|---|---|---|---|---|
| ANGO | AngioDynamics, Inc. | $10.97 | -0.54% | $13.99 | $8.27 | $452.2M | |
| APGE | Apogee Therapeutics, Inc. | $67.78 | -2.21% | $84.56 | $26.20 | $4.6B | |
| APM | Aptorum Group Limited | $0.78 | -8.24% | $4.47 | $0.65 | $6.4M | |
| BEAM | Beam Therapeutics Inc. | $27.92 | +3.68% | $36.44 | $13.53 | $2.8B | |
| BMY | Bristol-Myers Squibb Company | $60.72 | +1.44% | $63.33 | $42.52 | $123.7B | |
| CNC | Centene Corporation | $40.57 | +3.55% | $66.03 | $25.08 | $20.0B | |
| COCP | Cocrystal Pharma Inc | $0.96 | +3.23% | $2.19 | $0.86 | $13.3M | |
| CORT | Corcept Therapeutics Incorporated | $38.40 | +0.16% | $117.33 | $32.99 | $4.2B | |
| CRNX | Crinetics Pharmaceuticals, Inc. | $42.70 | -3.13% | $57.99 | $24.10 | $4.4B | |
| CYH | Community Health Systems, Inc. | $3.43 | -0.29% | $4.47 | $2.24 | $479.2M | |
| DHR | Danaher Corporation | $212.55 | -1.11% | $242.80 | $171.00 | $150.3B | |
| LLY | Eli Lilly and Company | $1040.45 | +0.38% | $1133.95 | $623.78 | $932.3B | |
| MDT | Medtronic plc. | $100.88 | -0.20% | $106.33 | $79.55 | $127.6B | |
| UNH | UnitedHealth Group Incorporated | $293.14 | +3.08% | $606.36 | $234.60 | $265.6B |
FDA approval decisions are binary events with large financial consequences. A single drug can represent billions in future revenue. When the FDA approves a drug, the company gains a years-long revenue stream; when it rejects one, years of R&D investment are written off. This creates 30-80% swings in smaller biotech stocks. Setting price alerts before known FDA decision dates (called PDUFA dates) helps investors react quickly.
Large-cap pharma companies like Johnson & Johnson, Pfizer, and AbbVie offer reliable dividends. Set dividend ex-date alerts to buy before the record date, P/E ratio below alerts at historical averages (12-15x) to identify value opportunities, and price below alerts at 52-week lows to catch overreaction selling during drug pricing headlines or patent cliff concerns.
Set volume change alerts at 300%+ to detect unusual trading activity that often precedes clinical trial results or FDA decisions. Combine with price change alerts at 10%+ to catch significant moves. For stocks with known PDUFA dates, set price above/below alerts at the current price a few days before the decision to capture the binary move in either direction.
Set up real-time alerts for healthcare stocks. Price targets, technical indicators, earnings, and more.